[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611645":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":26,"locations":32,"responsibleParty":92,"collaborators":96,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":23,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":23,"enrollmentInfo":109,"targetDuration":23,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":23,"overallStatus":35,"whyStopped":23,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Indiana University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SYSTANE® PRO","ACTIVE_COMPARATOR","SYSTANE® PRO is a preservative free artificial tear with a unique triple action formula that contains hyaluronate, nano-sized lipids, and HP-Guar.",[13],"Drug: SYSTANE® PRO",{"label":15,"type":10,"description":16,"interventionNames":17},"MIEBO™ (Perfluorohexyloctane, PFHO)","Perfluorohexyloctane (PFHO) ophthalmic solution, which is marketed in the United States as MIEBO™ (Bausch + Lomb; Rochester, NY, USA) is a preservative-free eye drop.",[18],"Drug: MIEBO™ (Perfluorohexyloctane, PFHO)",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DRUG",[9],null,{"type":21,"name":15,"description":16,"armGroupLabels":25,"otherNames":23},[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":23,"email":31},"Anna Tichenor, OD, PhD, FAAO","CONTACT","812-855-0520","annatich@iu.edu",[33,52,62,77],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Eye Research Foundation","RECRUITING","Newport Beach","California","92663","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-117.92895,33.61891,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":23,"email":51},"David Wirta, MD","949-650-1863","david.wirta@drwirta.com",{"facility":53,"status":35,"city":54,"state":55,"zip":56,"country":39,"countryCode":40,"cosmosGeoPoint":57,"geoPoint":61,"contacts":23},"Indiana Universtiy School of Optometry","Bloomington","Indiana","47408",{"type":42,"coordinates":58},[59,60],-86.52639,39.16533,{"lat":60,"lon":59},{"facility":63,"status":35,"city":64,"state":65,"zip":66,"country":39,"countryCode":40,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Kannarr Eye Care","Pittsburg","Kansas","66762",{"type":42,"coordinates":68},[69,70],-94.70496,37.41088,{"lat":70,"lon":69},[73],{"name":74,"role":29,"phone":75,"phoneExt":23,"email":76},"Shane Kannarr, OD","620-235-1737","skannarr@kannarreyecare.com",{"facility":78,"status":35,"city":79,"state":80,"zip":81,"country":39,"countryCode":40,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Southern College of Optometry","Memphis","Tennessee","38104",{"type":42,"coordinates":83},[84,85],-90.04898,35.14953,{"lat":85,"lon":84},[88],{"name":89,"role":29,"phone":90,"phoneExt":23,"email":91},"Chris Lievens, OD, MS, FNAP, FAAO","901-722-3250","clievens@sco.edu",{"type":93,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Anna Tichenor","Principal Investigator",[97],{"name":98,"class":99},"Alcon Research","INDUSTRY","100611645","phase-4-systane-pro-vs-miebo-in-dry-eye-disease-100611645",false,"NCT07243275","SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease","Comparing the Efficacy of SYSTANE® PRO to MIEBO™ for the Treatment of Dry Eye Disease","Inclusion Criteria:\n\n* Adults\\>=18 years of age\n* Corrected visual acuity of 20\u002F100 or better in both eyes\n* Ocular Surface Disease Index \\[OSDI\\] scores between 23 and 50 units \\[inclusive\\]\n* Tear break up time score of \\\u003C=5 seconds in both eyes\n* Schirmer I test (without anesthesia) \\>=5 mm in both eyes\n\nExclusion Criteria:\n\n* Discontinue contact lens wear starting 7 days prior and throughout the study\n* Artificial tears and warm compresses should not be used for at least one week prior to enrollment and throughout the study\n* Systemic health conditions that are known to alter tear film physiology(e.g., primary and secondary Sjogren's syndrome)\n* History of ocular surgery within the past 12 months\n* History of severe ocular trauma, active ocular infection or inflammation, have ever used Accutane or are currently using ocular medications.\n* Women who are pregnant or breast feeding(self report)\n* Subjects with a condition or in a situation, which in the investigator's opinion, may put the subject at significant rist, may confound the study results, or may significantly interfere with their participation in the study\n* Subjects will not be allowed to use any other topical eye drops or other dry eye treatments beyond their assignment during the study\n* Participants in clinical trial or study using a device, topical, or oral therapeutic in the past 3 months of enrollment","ALL","18 Years",{"count":110,"type":111},260,"ESTIMATED","INTERVENTIONAL",[114],"PHASE4","This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.",[117],"Dry Eye Disease (DED)","2026-03-26",{"date":120,"type":121},"2026-03-27","ACTUAL",{"date":123,"type":121},"2026-02-18",{"date":125,"type":111},"2026-09-30",{"name":5,"class":6},4]